NovaScan recently presented in a poster session at the 2018 Annual Meeting of the American Society of Breast Surgeons, where the company presented the results of a retrospective study that demonstrated that an elevated Cole frequency — which can be detected at the time of biopsy — has utility in predicting long term clinical outcomes.
